SELLAS Narrows Losses, Boosts Cash Reserves with $50M+ in Financing

TL;DR

**SELLAS is burning less cash and just secured a massive capital injection, making it a speculative buy for those betting on its cancer pipeline.**

AI Summary

SELLAS Life Sciences Group, Inc. reported a net loss of $6.791 million for the three months ended September 30, 2025, an improvement from a net loss of $7.108 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $19.205 million, a significant reduction from $24.144 million in the prior year. Research and development expenses decreased to $11.292 million for the nine months ended September 30, 2025, from $14.659 million in 2024, while general and administrative expenses also fell to $8.727 million from $9.936 million. The company's cash and cash equivalents surged to $44.320 million as of September 30, 2025, up from $13.886 million at December 31, 2024, primarily due to significant financing activities. These activities included $22.0 million in net proceeds from a September 2025 warrant inducement, $23.1 million from a January 2025 registered direct offering, and $8.7 million from warrant exercises. Post-quarter, an October 2025 warrant inducement generated an additional $29.1 million in net proceeds. The company expects its current cash, combined with the October 2025 proceeds, to fund operations for at least the next twelve months, despite an accumulated deficit of $267.3 million.

Why It Matters

SELLAS's ability to significantly reduce its net loss and bolster its cash position through multiple financing rounds is crucial for investors, signaling improved financial stability for its late-stage clinical programs, GPS and SLS009. This influx of capital, totaling over $50 million from warrant inducements and offerings, extends its operational runway, which is vital in the capital-intensive biopharmaceutical sector. For employees and customers, continued funding means greater certainty in the progression of potential cancer therapeutics. In a competitive market, this financial resilience allows SELLAS to advance its pipeline, potentially challenging larger players in oncology if its clinical trials yield positive data.

Risk Assessment

Risk Level: medium — While SELLAS has significantly improved its cash position to $44.3 million as of September 30, 2025, and secured an additional $29.1 million post-quarter, the company still faces substantial risks. It has an accumulated deficit of $267.3 million and continues to incur recurring losses, with a net loss of $19.2 million for the nine months ended September 30, 2025. The company explicitly states it will need additional funding beyond the next twelve months, and there's no guarantee of obtaining it on favorable terms, which could lead to significant dilution or program curtailment.

Analyst Insight

Investors should monitor SELLAS's clinical trial progress for GPS and SLS009 closely, as the recent capital raises provide a longer runway for these programs. Given the company's history of dilution through warrant inducements and offerings, potential investors should factor in future equity raises and their impact on share value. This is a high-risk, high-reward play contingent on clinical success.

Financial Highlights

debt To Equity

0.13

revenue

$0

operating Margin

N/A

total Assets

$51.6M

total Debt

$5.9M

net Income

-$19.2M

eps

-$0.20

gross Margin

N/A

cash Position

$44.3M

revenue Growth

N/A

Key Numbers

• $44.3M — Cash and Cash Equivalents (Increased from $13.9M at Dec 31, 2024, a 218% increase, providing liquidity.)
• $19.2M — Net Loss (9 months) (Reduced from $24.1M in prior year, indicating improved operational efficiency.)
• $23.5M — Cash Used in Operations (9 months) (Lower than $28.2M in prior year, reflecting reduced cash burn.)
• $29.1M — October 2025 Inducement Proceeds (Additional capital secured post-quarter, extending cash runway.)
• $22.0M — September 2025 Inducement Proceeds (Significant capital infusion during the quarter.)
• $23.1M — January 2025 Offering Proceeds (Key financing event contributing to increased cash.)
• $267.3M — Accumulated Deficit (Indicates historical losses and the need for future profitability.)
• 125,078,525 — Shares Outstanding (Increased from 73,977,459 at Dec 31, 2024, reflecting significant dilution.)

Key Players & Entities

• SELLAS Life Sciences Group, Inc. (company) — registrant
• Memorial Sloan Kettering Cancer Center (company) — licensor of GPS
• GenFleet Therapeutics (Shanghai), Inc. (company) — licensor of SLS009
• 3D Medicines Inc. (company) — licensee of GPS in 3DMed Territory
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• $44.3 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $29.1 million (dollar_amount) — net proceeds from October 2025 Warrant Inducement
• $22.0 million (dollar_amount) — net proceeds from September 2025 Warrant Inducement
• $23.1 million (dollar_amount) — net proceeds from January 2025 Registered Direct Offering
• $267.3 million (dollar_amount) — accumulated deficit as of September 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $267.3 million and expects its current cash, augmented by $29.1 million in post-quarter financing, to fund operations for at least twelve months. Failure to secure additional funding could force curtailment or discontinuation of R&D programs.
• Dilutive Financing [medium — financial]: Significant financing activities, including a $23.1 million registered direct offering in January 2025 and warrant exercises, have led to an increase in shares outstanding from 73.9 million to 125.1 million. Future financing may be dilutive to existing stockholders.
• 3D Medicines Arbitration [medium — legal]: A binding arbitration proceeding was commenced in December 2023 against 3D Medicines concerning milestone payments related to the GPS product candidate license. The outcome of this arbitration could impact future revenue recognition and cash flows.
• Clinical Development Risks [high — operational]: The company's primary focus is on developing novel therapeutics, specifically galinpepimut-S (GPS) and SLS009. Success is contingent on achieving clinical development goals, regulatory approvals, and eventual commercialization, all of which carry inherent risks.
• Regulatory Approval Pathway [high — regulatory]: As a biopharmaceutical company, SELLAS is subject to stringent regulatory review processes by bodies like the FDA. Delays or failures in obtaining regulatory approval for its product candidates can significantly impact the company's prospects.

Industry Context

SELLAS operates in the late-stage clinical biopharmaceutical sector, focusing on novel cancer therapeutics. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Success hinges on clinical trial outcomes and regulatory approvals, with a competitive landscape driven by innovation in immunotherapy and targeted therapies.

Regulatory Implications

As a biopharmaceutical company, SELLAS is subject to rigorous regulatory oversight from agencies like the FDA. The development and potential commercialization of its product candidates, GPS and SLS009, require adherence to strict guidelines. Any delays or failures in the regulatory approval process pose a significant risk to the company's business model and financial viability.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for GPS and SLS009.
2. Assess the company's ability to manage its cash burn and secure future funding.
3. Evaluate the impact of ongoing litigation and potential milestone payments.
4. Consider the dilutive effects of past and potential future equity issuances.

Key Dates

• 2025-10-24: October 2025 Warrant Inducement — Secured approximately $29.1 million in net proceeds, significantly extending the company's cash runway for at least the next twelve months.
• 2025-09-10: September 2025 Warrant Inducement — Generated $22.0 million in net proceeds from warrant exercises, bolstering cash reserves.
• 2025-01-01: January 2025 Registered Direct Offering — Raised $23.1 million, a key financing event that contributed to the substantial increase in cash position.
• 2025-09-30: Q3 2025 Financial Reporting — Reported a net loss of $6.8 million for the quarter and $19.2 million for the nine months, showing reduced losses compared to the prior year. Cash position increased significantly to $44.3 million.
• 2024-12-31: Year-End 2024 Financial Reporting — Reported cash and cash equivalents of $13.9 million, highlighting the substantial improvement in liquidity by Q3 2025.

Glossary

Galinpepimut-S (GPS)

A cancer immunotherapeutic agent targeting the Wilms Tumor 1 (WT1) protein, licensed from Memorial Sloan Kettering Cancer Center. (SELLAS' lead product candidate, central to its development strategy and future revenue potential.)

SLS009 (tambiciclib)

A small molecule, selective cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics. (SELLAS' second product candidate, offering potential for monotherapy or combination treatments in various cancers.)

Warrant Inducement

An agreement where a company offers incentives for holders of existing warrants to exercise them early, often in exchange for new warrants. (Key financing mechanism used by SELLAS to raise substantial capital, as seen in the September and October 2025 events.)

Accumulated Deficit

The cumulative net losses of a company since its inception, representing the total amount by which losses have exceeded profits. (Indicates SELLAS' history of losses and the significant capital required to reach profitability.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. Disclosures are required if substantial doubt exists. (The company's disclosures indicate they have evaluated and expect to continue as a going concern, supported by recent financing.)

Registered Direct Offering

A type of public offering where a company sells a significant block of securities directly to a small number of institutional investors. (A major source of capital for SELLAS, contributing $23.1 million in January 2025.)

Year-Over-Year Comparison

Compared to the prior year, SELLAS has significantly improved its liquidity, with cash and cash equivalents soaring from $13.9 million to $44.3 million as of September 30, 2025. This was driven by substantial financing activities, including warrant inducements and a registered direct offering. The company has also reduced its net loss for both the three and nine-month periods, indicating improved operational efficiency with lower R&D and G&A expenses. However, the number of outstanding shares has increased substantially, from approximately 74 million to 125 million, reflecting significant dilution from financing activities.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq Stoc

Filing Documents

• sls-20250930.htm (10-Q) — 731KB
• sls-20250930ex311.htm (EX-31.1) — 8KB
• sls-20250930ex312.htm (EX-31.2) — 8KB
• sls-20250930ex321.htm (EX-32.1) — 6KB
• sls-20250930ex322.htm (EX-32.2) — 6KB
• sls-20250930_g1.jpg (GRAPHIC) — 30KB
• 0001390478-25-000020.txt ( ) — 4283KB
• sls-20250930.xsd (EX-101.SCH) — 35KB
• sls-20250930_cal.xml (EX-101.CAL) — 37KB
• sls-20250930_def.xml (EX-101.DEF) — 127KB
• sls-20250930_lab.xml (EX-101.LAB) — 453KB
• sls-20250930_pre.xml (EX-101.PRE) — 310KB
• sls-20250930_htm.xml (XML) — 476KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1 Financial Statements 4 Unaudited Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 4 Unaudited Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 5 Unaudited Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Unaudited Notes to Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 20

Quantitative and Qualitative Disclosures About Market Risk

Item 3 Quantitative and Qualitative Disclosures About Market Risk 29

Controls and Procedures

Item 4 Controls and Procedures 29

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings 30

Item 1 Legal Proceedings 30

Risk Factors 30

Item 1A Risk Factors 30

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 30

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 30

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 30

Other Information

Item 5 Other Information 30

Signatures

Signatures The names "SELLAS Life Sciences Group, Inc.," "SELLAS," the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies. Unless the context otherwise indicates, references in these notes to the "Company," "we," "us" or "our" refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. 1 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words "expect," "intend," "plan," "believe," "project," "estimate," "may," "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements and include, without limitation, statements regarding: our future financial and business performance; strategic plans for our business and product candidates; our ability to develop or commercialize products; the expected results and timing of clinical trials and nonclinical studies; our ability to comply with the terms of our license agreements; developments and projections relating to our competitors and industry; our expectations regarding our ability to obtain, develop and maintain intellectual property protection and not infringe on the righ

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share data) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 44,320 $ 13,886 Restricted cash and cash equivalents 100 100 Prepaid expenses and other current assets 4,631 2,341 Total current assets 49,051 16,327 Operating lease right-of-use assets 556 925 Goodwill 1,914 1,914 Deposits and other assets 34 266 Total assets $ 51,555 $ 19,432 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,305 $ 3,500 Accrued expenses and other current liabilities 3,021 5,466 Operating lease liabilities 599 544 Total current liabilities 5,925 9,510 Operating lease liabilities, non-current — 457 Total liabilities 5,925 9,967 Commitments and contingencies (Note 5) Stockholders' equity: Common stock, $ 0.0001 par value; 350,000,000 shares authorized, 125,078,525 and 73,977,459 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 12 7 Additional paid-in capital 312,948 257,583 Accumulated deficit ( 267,330 ) ( 248,125 ) Total stockholders' equity 45,630 9,465 Total liabilities and stockholders' equity $ 51,555 $ 19,432 See accompanying notes to these unaudited consolidated financial statements. 4 Table of Contents SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share data) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 4,216 $ 4,362 $ 11,292 $ 14,659 General and administrative 2,867 2,967 8,727 9,936 Total operating expenses 7,083 7,329 20,019 24,595 Loss from operations ( 7,083 ) ( 7,329 ) ( 20,019 ) ( 24,595 ) Non-operating income: Interest income 292 221 814 451 Total non-operating income 292 221 814 451 Net loss $ ( 6,791 )

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1. Organization and Description of Business Overview SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. SELLAS' second product candidate is SLS009 (tambiciclib), a small molecule, highly selective cyclin-dependent kinase 9 ("CDK9") inhibitor, which the Company licensed from GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau and Taiwan ("SLS009 Territory"). Each of GPS and SLS009 has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. 2. Liquidity On October 24, 2025, the Company entered into a Warrant Inducement Agreement (the "October 2025 Inducement") with an institutional investor and holder of certain existing warrants to cash exercise (i) warrants to purchase 6,514,658 shares of common stock at an exercise price of $ 1.535 per share, previously issued in March 2024 (the "March 2024 Warrants"), and (ii) warrants to purchase 15,849,056 shares of common stock at an exercise price of $ 1.325 per share, previously issued in August 2024 (the "August 2024 Warrants"). The March 2024 Warrants and the August 2024 Warrants were exercised at their original issuance exercise price plus $ 0.125 per share of common stock in accordance with Nasdaq rules. In consideration of the investor's agreement to exercise the March 2024 Warrants and the August 2024 Warrants, the Company agreed to issue new warrants to the investor to purchase up to 22,363,714 shares

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued (Unaudited) pursuant to which the Company granted 3D Medicines a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS product candidates for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). As of September 30, 2025, the Company has received an aggregate of $ 10.5 million in upfront payments and certain technology transfer and regulatory milestones. There is a total of $ 191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, that remains under the 3D Medicines Agreement, which milestones are all variable in nature and not under the Company's control. In December 2023, the Company commenced a binding arbitration proceeding against 3D Medicines, which involves, among other things, the trigger and payment of certain milestone payments due to the Company. See Note 5 . Legal Proceedings. As of September 30, 2025, the Company had cash and cash equivalents of approximately $ 44.3 million and restricted cash and cash equivalents of $ 0.1 million. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern , the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with the approximately $ 29.1 million in net proceeds from the October 2025 Inducement, will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements, although the Company may pursue additional

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued (Unaudited) The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company, SLSG Limited, LLC, and Sellas Life Sciences Limited. The functional currency of the Company's non-U.S. operations is the U.S. dollar. Unaudited Interim Results These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2024 Annual Report. The accompanying consolidated financial statements as of September 30, 2025 and for the three and nine months ended September 30, 2025 and 2024, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2024 have been derived from the audited financial statements as of that date. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company's chief operating decision maker ("CODM") is the President & Chief Executive Officer. The Company views its operations and manages its business as one operating segment, which includes all activities related to the development of novel therapeutics for a broad range of cancer indicat

View Full Filing

View this 10-Q filing on SEC EDGAR